AbbVie: You’re Upgrading It…Now?
October 11, 2017 at 15:40 PM EDT
Cowen upgraded the drug maker to an Outperform, arguing that the stock can still reach $105 a share even after it posted a 47% rise over the past 12 months. Here's why.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.